Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Edoardo, Lanino"'
Autor:
Rossella Parini, Federica Deodato, Maja Di Rocco, Edoardo Lanino, Franco Locatelli, Chiara Messina, Attilio Rovelli, Maurizio Scarpa
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-9 (2017)
Abstract Mucopolysaccharidosis I-Hurler (MPS I-H) is the most severe form of a metabolic genetic disease caused by mutations of IDUA gene encoding the lysosomal α-L-iduronidase enzyme. MPS I-H is a rare, life-threatening disease, evolving in multisy
Externí odkaz:
https://doaj.org/article/cfa741142ece4f568cd344f804fa569f
Autor:
Roberta Caorsi, Marta Rusmini, Stefano Volpi, Sabrina Chiesa, Claudia Pastorino, Angela Rita Sementa, Paolo Uva, Alice Grossi, Edoardo Lanino, Maura Faraci, Francesca Minoia, Sara Signa, Paolo Picco, Alberto Martini, Isabella Ceccherini, Marco Gattorno
Publikováno v:
Frontiers in Immunology, Vol 8 (2018)
Primary immunodeficiencies with selective susceptibility to EBV infection are rare conditions associated with severe lymphoproliferation. We followed a patient, son of consanguineous parents, referred to our center for recurrent periodic episodes of
Externí odkaz:
https://doaj.org/article/b2bdffbf61a248c1a7973c27c4011b96
Autor:
Filomena Pierri, Gian Michele Magnano, Edoardo Lanino, Stefano Giardino, Francesca Bagnasco, Donata Girosi, Elio Castagnola, Maura Faraci, Roberta Olcese, Erica Ricci
Publikováno v:
Pediatric Pulmonology. 55:631-637
Background The onset of bronchiolitis obliterans (BO) as a pulmonary manifestation of chronic graft vs host disease dramatically changes the prognosis of children undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::601b18102432b3c96d58d2951fdce4e3
https://doi.org/10.1002/ppul.24652
https://doi.org/10.1002/ppul.24652
Autor:
Stefano, Giardino, Francesca, Bagnasco, Michela, Falco, Maurizio, Miano, Filomena, Pierri, Marco, Risso, Paola, Terranova, Daniela, Di Martino, Erika, Massaccesi, Margherita, Ricci, Benedetta, Chianucci, Gianluca, Dell'Orso, Federica, Sabatini, Marina, Podestà, Edoardo, Lanino, Maura, Faraci
Publikováno v:
Transplantation and cellular therapy. 28(7)
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) represents a valuable alternative for children with nonmalignant disease and ex vivo negative selection of TCR-αβ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1d43bf1350e2049d09336904278456a0
https://pubmed.ncbi.nlm.nih.gov/35405368
https://pubmed.ncbi.nlm.nih.gov/35405368
Autor:
Erica Ricci, Elio Castagnola, Stefano Giardino, Maria Grazia Calevo, Edoardo Lanino, Massimiliano Leoni, Maura Faraci
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:743-748
Corticosteroids are the standard of care for first-line treatment of patients who develop grade II-IV of acute graft-versus-host disease (aGVHD), but the optimal second-line treatment has not yet been determined. We prospectively evaluated the use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f6d0327e724792edc278d309bfbc1a8
https://doi.org/10.1016/j.bbmt.2018.11.017
https://doi.org/10.1016/j.bbmt.2018.11.017
Autor:
Thierry Levade, Monika Führer, Tayfun Güngör, Maja Di Rocco, Francis Ayuk, Michael H. Albert, Josef Vormoor, Karoline Ehlert, Edoardo Lanino, Andrea Jarisch
Publikováno v:
Journal of Inherited Metabolic Disease. 42:286-294
Farber disease (FD) is a rare, lysosomal storage disorder caused by deficient acid ceramidase activity. FD has long been considered a fatal disorder with death in the first three decades of life resulting either from respiratory insufficiency as a co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e30fe3e6f7ce65dd9ac9f74ca9af08bf
https://doi.org/10.1002/jimd.12043
https://doi.org/10.1002/jimd.12043
Autor:
Stefano Giardino, Francesca Bagnasco, Michela Falco, Maurizio Miano, Filomena Pierri, Marco Risso, Paola Terranova, Daniela Di Martino, Erika Massaccesi, Margherita Ricci, Benedetta Chianucci, Gianluca Dell'Orso, Federica Sabatini, Marina Podestà, Edoardo Lanino, Maura Faraci
Publikováno v:
Transplantation and Cellular Therapy. 28:394.e1-394.e9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5d4a9176d5f2490140d23f05ffbf960
https://doi.org/10.1016/j.jtct.2022.04.002
https://doi.org/10.1016/j.jtct.2022.04.002
Autor:
Franca Fagioli, Paola Quarello, Marco Zecca, Edoardo Lanino, Carla Rognoni, Adriana Balduzzi, Chiara Messina, Claudio Favre, Roberto Foà, Mimmo Ripaldi, Sergio Rutella, Giuseppe Basso, Arcangelo Prete, Franco Locatelli
Publikováno v:
Haematologica, Vol 98, Iss 8 (2013)
Children with high-risk acute lymphoblastic leukemia in first complete remission can benefit from allogeneic hematopoietic stem cell transplantation. We analyzed the outcome of 211 children with high-risk acute lymphoblastic leukemia in first complet
Externí odkaz:
https://doaj.org/article/66325dffdf7b470e88ab75d04e746d8f
Autor:
Matteo Puntoni, Massimo Conte, Enrica Bertelli, Vania Altrinetti, Edoardo Lanino, Alberto Garaventa, Stefano Giardino, Maura Faraci, Arnoldo Piccardo, Stefania Sorrentino, Mariapina Montera, Ilaria Caviglia, Marco Risso
Publikováno v:
Pediatric Blood & Cancer. 68
Introduction Despite the progress in current treatments, the event-free survival of high-risk neuroblastoma (HR-NB) patients does not exceed 40%-50%, and the prognosis of refractory or relapsed patients is poor, still representing a challenge for ped
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bff932441b76409e344392bc009c8cce
https://doi.org/10.1002/pbc.28775
https://doi.org/10.1002/pbc.28775
Autor:
Enrica Bertelli, Stefano Giardino, Marco Risso, Alberto Garaventa, Maura Faraci, Mariapina Montera, Edoardo Lanino, Stefania Sorrentino, Arnoldo Piccardo, Ilaria Caviglia, Matteo Puntoni, Vania Altrinetti, Massimo Conte
Introduction.Despite progress obtained with current treatments,the event-free survival of high-risk neuroblastoma(HR-NB)patients does not exceed 40-50% and the prognosis in refractory or relapsed patients is poor,still representing a challenge for pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4884b2c12d4f4e81ded85c495c5389a0
https://doi.org/10.22541/au.159407041.12926138
https://doi.org/10.22541/au.159407041.12926138
